The treatment of type 2 diabetes
- PMID: 24612534
- PMCID: PMC3952010
- DOI: 10.3238/arztebl.2014.0069
The treatment of type 2 diabetes
Abstract
Background: 5% to 8% of adults have type 2 diabetes, a disease that is usually asymptomatic at first. The goals of management are timely diagnosis and the prevention of complications.
Methods: Selective review of the literature, including guidelines from Germany and abroad.
Results: High caloric intake and lack of exercise are the main contributing causes of type 2 diabetes and the principal targets of intervention. If lifestyle changes do not yield adequate improvement, then drug treatment should be initiated (or intensified) and managed on the basis of the HbA1c fraction. Guidelines recommend an HbA1c target range of 6.5% to 7.5%; the individual target value should be chosen in consideration of patient-specific factors and established in collaboration with the patient. Metformin is recommended for initial drug treatment. If metformin is contraindicated, poorly tolerated, or inadequately effective, many therapeutic alternatives and supplements are available. Clinical trials have shown that sulfonylureas and insulin are beneficial with respect to patient-relevant endpoints, but comparable data from clinical trials are not yet available for any other antidiabetic drug (except metformin). For individual patients, other drugs may have advantages such as a lower risk of hypoglycemia, less weight gain, oral administration, and/or applicability in the setting of renal insufficiency. The treatment is individually oriented, depending on the patient's age, disease stage, body weight, comorbidities, work situation, adherence, and personal priorities. Combining more than two antidiabetic drugs is not recommended.
Conclusion: Although there are many treatment options, individualized long-term treatment still presents a challenge in many cases.
Figures
Comment in
-
Too much alcohol.Dtsch Arztebl Int. 2014 Jun 20;111(25):432. doi: 10.3238/arztebl.2014.0432a. Dtsch Arztebl Int. 2014. PMID: 25008302 Free PMC article. No abstract available.
-
General practitioners were neglected.Dtsch Arztebl Int. 2014 Jun 20;111(25):432. doi: 10.3238/arztebl.2014.0432b. Dtsch Arztebl Int. 2014. PMID: 25008303 Free PMC article. No abstract available.
-
Limited prospects of success.Dtsch Arztebl Int. 2014 Jun 20;111(25):432-3. doi: 10.3238/arztebl.2014.0432c. Dtsch Arztebl Int. 2014. PMID: 25008304 Free PMC article. No abstract available.
-
Skepticism is unjustified.Dtsch Arztebl Int. 2014 Jun 20;111(25):433. doi: 10.3238/arztebl.2014.0433a. Dtsch Arztebl Int. 2014. PMID: 25008305 Free PMC article. No abstract available.
-
In reply.Dtsch Arztebl Int. 2014 Jun 20;111(25):433-4. doi: 10.3238/arztebl.2014.0433b. Dtsch Arztebl Int. 2014. PMID: 25008306 Free PMC article. No abstract available.
References
-
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2012;55:1577–1596. - PubMed
-
- Paulweber B, Valensi P, Lindstrom J, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010 42;(Suppl 1):3–36. - PubMed
-
- Imamura M, Maeda S. Genetics of type 2 diabetes: the GWAS era and future perspectives. Endocr J. 2011;58:723–739. - PubMed
-
- Europe I. Diabetes Atlas. 4th edition. 2009. The International Diabetes Federation. www.idf.org/atlasmap/atlasmap (Last accessed on 13 Januaray 2014) - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
